Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GALMED PHARMACEUTICALS LTD.

(GLMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MHRA Agrees with Galmed's Plan to Use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 Armor Study

08/16/2021 | 08:00am EST

Galmed Pharmaceuticals Ltd. announced that the Medicines and Healthcare products Regulatory Agency (MHRA), agreed with Galmed's plan to proceed with its proposed clinical studies with Aramchol meglumine in lieu of Aramchol free acid without the need to repeat nonclinical and clinical studies other than planned limited pharmacology studies relating to Aramchol meglumine. This follows similar agreement received from the FDA that was recently announced. Aramchol meglumine is an improved compound using a salt form of Aramchol that has significantly greater water solubility than the free acid and an NCE patent protection valid until December 2034. Aramchol meglumine circulates in the blood as Aramchol.


ę S&P Capital IQ 2021
All news about GALMED PHARMACEUTICALS LTD.
11/08Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of AR..
PU
11/08GALMED PHARMACEUTICALS : Q3 Earnings Snapshot
AQ
11/08Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Mon..
CI
11/08Galmed Pharmaceuticals Ltd. Announces New Positive Data from Ongoing ARMOR Study Open L..
CI
11/01—Data demonstrates that treatment with Aramchol 300mg BID resulted in clinically ..
PU
11/01Galmed Pharmaceuticals Ltd. Announces Positive Results from First 16 Patients in Open-L..
CI
10/12GALMED PHARMACEUTICALS : Results of Galmed's Phase 2b ARREST Trial of Aramchol Published i..
PU
10/11GALMED PHARMACEUTICALS : Results of Galmed's Phase 2b ARREST Trial of Aramchol Published i..
PR
10/11Galmed Pharmaceuticals Ltd. Announces One-Year Results of Global Phase 2b Randomized Pl..
CI
09/20GALMED PHARMACEUTICALS LTD.(NASDAQCM : GLMD) dropped from S&P Global BMI Index
CI
More news
Analyst Recommendations on GALMED PHARMACEUTICALS LTD.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -33,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,97x
Yield 2021 -
Capitalization 63,7 M 63,7 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 21
Free-Float 86,0%
Chart GALMED PHARMACEUTICALS LTD.
Duration : Period :
Galmed Pharmaceuticals Ltd. Technical Analysis Chart | GLMD | IL0011313900 | MarketScreener
Technical analysis trends GALMED PHARMACEUTICALS LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2,54 $
Average target price 17,60 $
Spread / Average Target 593%
EPS Revisions
Managers and Directors
Allen Baharaff Chairman, President & Chief Executive Officer
Yohai Stenzler Chief Financial Officer
Liat Hayardeny Chief Scientific Officer
Guy Nehemya Chief Operating Officer
Shmuel Nir Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GALMED PHARMACEUTICALS LTD.-18.33%64
GILEAD SCIENCES, INC.21.27%88 622
BIONTECH SE344.70%87 556
REGENERON PHARMACEUTICALS35.46%68 421
WUXI APPTEC CO., LTD.27.38%66 062
VERTEX PHARMACEUTICALS-19.56%48 336